Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Comment by prophetoffactzon Dec 30, 2022 8:40am
181 Views
Post# 35196674

RE:RE:RE:RE:New Article

RE:RE:RE:RE:New ArticleCEO buys another $67,000 since last post.

prophetoffactz wrote: CEO buys another $14,140 worth of stock as he continues to add to his holdings.

prophetoffactz wrote: CEO buys another $16,720 worth of stock further adding to his recent buys.


$16,720

+15,200 vol
$1.10 each

prophetoffactz wrote: The CEO has now bought >$71,000 worth of shares in recent months having added another $11,000 last Friday.

prophetoffactz wrote: As the CEO continues to buy shares here's a new article suggesting why. Some of the top clinicians in the world are involved with a study about to commence in Q4. Approval could be a game-changer. MPH has already received a Priority Review Voucher that could be worth US$100-US$200 million.

Pg. 20:
Insights Magazine - BIOTECanada (biotech.ca)

 








<< Previous
Bullboard Posts
Next >>